A fusion protein comprising nil2 and iRGD and its use in the preparation of an anti-tumor drug
The fusion protein of NIL2 and iRGD forms an anti-tumor immunotherapy drug with dual synergistic effects by linking iRGD to the C-terminus of NIL2. This solves the side effect risks and drug interaction problems in the co-administration of IL-2 and iRGD, and achieves a highly efficient and safe tumor treatment effect.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- XINXIANG MEDICAL UNIV
- Filing Date
- 2026-06-05
- Publication Date
- 2026-07-17
AI Technical Summary
The co-administration of IL-2 and iRGD in cancer treatment presents problems such as the risk of overlapping side effects, uncontrollable drug interactions, and amplified individual tolerance differences, which affect the treatment efficacy and safety.
A fusion protein of NIL2 and iRGD was designed, and iRGD was linked to the C-terminus of NIL2 to form an anti-tumor immunotherapy drug with dual synergistic effects. NIL2 acts as an immune-activating effector molecule, and iRGD acts as a tumor penetration carrier, which enhances drug delivery efficiency and promotes tumor tissue penetration.
It significantly reduces the IL-2 dose, activates the tumor immune response, improves drug utilization, reduces vascular permeability toxicity, enhances anti-tumor effects, reduces side effects, and improves drug administration safety.
Smart Images
Figure CN122404574A_ABST